Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03085056 · ClinicalTrials.gov registry record · Early Phase 1
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
A Early Phase 1 study of Anaplastic Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 7
- Study locations
NCT03085056: Active Early Phase 1 study of Anaplastic Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03085056 is a Early Phase 1 study of Anaplastic Thyroid Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants, below the 26-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (50% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03085056, a Early Phase 1 study of Anaplastic Thyroid Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
Primary Outcome
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Trametinib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
What the registry record for NCT03085056 still lists
NCT03085056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 26-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Anaplastic Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03085056 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03085056 about?
NCT03085056 is a clinical study titled "Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer". The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
What is the current status of trial NCT03085056?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2017-03-15. Estimated completion is 2026-09.
What conditions does trial NCT03085056 study?
This clinical trial studies the following conditions: Anaplastic Thyroid Cancer.
What interventions are being tested in trial NCT03085056?
The interventions under investigation include: Paclitaxel (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT03085056?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03085056 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
COMPLETED · Phase 1
-
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI